# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-26-003439
**Filing Date:** 2026-4
**Character Count:** 51833
**Document Hash:** 2ed4a39705edfa5bc5b80fd01de04c1c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-003439.hdr.sgml**: 20260413

**ACCESSION NUMBER**: 0001654954-26-003439

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260413

**FILED AS OF DATE**: 20260413

**DATE AS OF CHANGE**: 20260413

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 26856901

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April 2026

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

 **GSK plc (the 'Company')**

Transaction notification

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | David Redfern | David Redfern |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | President Corporate Development | President Corporate Development |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April on Ordinary Shares held within an ISA | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April on Ordinary Shares held within an ISA |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.6962<br>| 17 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | <br> Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-10 | 2026-04-10 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Victoria Whyte | Victoria Whyte |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | SVP & Company Secretary | SVP & Company Secretary |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held within an ISA | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held within an ISA |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.6962<br>| 15 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | <br> Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-10 | 2026-04-10 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | David Redfern | David Redfern |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | President Corporate Development | President Corporate Development |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.6967<br>| 6 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | <br> Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-10 | 2026-04-10 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Neil Falkingham | Neil Falkingham |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | PCA of Lynn Baxter (President, Europe) | PCA of Lynn Baxter (President, Europe) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.6967<br>| 6 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | <br> Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-10 | 2026-04-10 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Luke Miels | Luke Miels |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | Chief Executive Officer | Chief Executive Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039<br>| 2393.328 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | <br> Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Lynn Baxter | Lynn Baxter |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | President, Europe | President, Europe |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039<br>| 253.610 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction<br>| 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Diana Conrad | Diana Conrad |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | Chief People Officer | Chief People Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039<br>| 1576.715 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Mike Crichton | Mike Crichton |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | President, International | President, International |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039 | 108.369<br>|
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | James Ford | James Ford |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | SVP and Group General Counsel, Legal and Compliance | SVP and Group General Counsel, Legal and Compliance |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039 | 1715.336<br>|
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Nina Mojas | Nina Mojas |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | President, Global Product Strategy | President, Global Product Strategy |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039<br>| 209.638 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | David Redfern | David Redfern |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | President Corporate Development | President Corporate Development |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039 | 5562.951<br>|
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Regis Simard | Regis Simard |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | President, Global Supply Chain | President, Global Supply Chain |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039 | 2866.619<br>|
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction<br>| 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Philip Thomson | Philip Thomson |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | President, Global Affairs | President, Global Affairs |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039 | 2305.556<br>|
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Deborah Waterhouse | Deborah Waterhouse |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | CEO, ViiV Healthcare and President, Global Health, GSK |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039 | 1025.671<br>|
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Tony Wood | Tony Wood |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | Chief Scientific Officer | Chief Scientific Officer |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039<br>| 2179.016 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Neil Falkingham | Neil Falkingham |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | PCA of Lynn Baxter (President, Europe) | PCA of Lynn Baxter (President, Europe) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039 | 144.438<br>|
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp; **1.** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** | **Details of PDMR/person closely associated with them ('PCA')** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | Kate Thomson | Kate Thomson |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Position/status | PCA of Philip Thomson (President, Global Affairs) | PCA of Philip Thomson (President, Global Affairs) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Initial notification/amendment | Initial notification | Initial notification |
| &nbsp;&nbsp;&nbsp;&nbsp; **2.** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Name | GSK plc | GSK plc |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | LEI | 5493000HZTVUYLO1D793 | 5493000HZTVUYLO1D793 |
| &nbsp;&nbsp;&nbsp;&nbsp; **3.** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted** |
| &nbsp;&nbsp;&nbsp;&nbsp; a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br>ISIN: GB00BN7SWP63 |
| &nbsp;&nbsp;&nbsp;&nbsp; b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026. |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) | £21.5039<br>| 95.573 |
| &nbsp;&nbsp;&nbsp;&nbsp; c) | Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated information<br>| N/A (single transaction) | N/A (single transaction) |
| &nbsp;&nbsp;&nbsp;&nbsp; d) | Aggregated volume<br>Price<br>|  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; e) | Date of the transaction | 2026-04-09 | 2026-04-09 |
| &nbsp;&nbsp;&nbsp;&nbsp; f) | Place of the transaction<br>| London Stock Exchange (XLON) | London Stock Exchange (XLON) |

---

 **About GSK**

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <u>www.gsk.com</u>.

 **Registered in England & Wales:**

No. 3888792 <br>

 **Registered Office:**

79 New Oxford Street

London

WC1A 1DG <br>

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: April 13, 2026 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---